Lexeo Therapeutics Files 8-K

Ticker: LXEO · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1907108

Lexeo Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLexeo Therapeutics, Inc. (LXEO)
Form Type8-K
Filed DateJul 15, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, corporate-update

Related Tickers: LXEO

TL;DR

Lexeo Therapeutics filed an 8-K, likely with updates. Check for details.

AI Summary

Lexeo Therapeutics, Inc. filed an 8-K on July 15, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates that Lexeo Therapeutics is providing updates to the SEC, which could relate to significant corporate events or financial performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate negative or positive financial disclosures in the provided text.

Key Players & Entities

  • Lexeo Therapeutics, Inc. (company) — Registrant
  • July 15, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 212 547-9879 (phone_number) — Registrant's Telephone Number
  • 345 Park Avenue South, Floor 6 (address) — Principal Executive Offices

FAQ

What specific events are being reported in this 8-K filing by Lexeo Therapeutics?

The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not specify the nature of these events or the content of the financial statements.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated July 15, 2024.

What is Lexeo Therapeutics' principal executive office address?

Lexeo Therapeutics' principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York 10010.

What is the Commission File Number for Lexeo Therapeutics?

Lexeo Therapeutics' Commission File Number is 001-41855.

What is the IRS Employer Identification Number for Lexeo Therapeutics?

Lexeo Therapeutics' IRS Employer Identification Number is 85-4012572.

Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-07-15 07:55:24

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo

Filing Documents

01 Other Events

Item 8.01 Other Events. On July 15, 2024, the Company issued a press release announcing positive interim Phase 1/2 clinical data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on July 15, 2024 to discuss the interim Phase 1/2 clinical data of LX2006 for the treatment of FA cardiomyopathy. The press release and the corporate presentation to be used in connection with the webcast are attached hereto as Exhibit 99.1 and 99.2, respectively, and are incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated July 15, 2024 99.2 104 Corporate Presentation, dated July 15, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: July 15, 2024 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.